Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report

In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020

(2022) James A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review

(2022) Angela Raffaella Losito et al.   Antibiotics-Basel

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)

(2022) Helio S Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model

(2021) Maxwell J. Lasko et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa

(2020) Bartolome Moya et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems

(2020) James A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of cefiderocol, a siderophore-cephalosporin, against multidrug-resistant gram-negative bacteria

(2020) Shazad Mushtaq et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update

(2020) Ester del Barrio-Tofiño et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)

(2019) Brian T. Tsuji et al.   PHARMACOTHERAPY

In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model

(2019) Marguerite L. Monogue et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A large-scale whole-genome comparison shows that experimental evolution in response to antibiotics predicts changes in naturally evolved clinical Pseudomonas aeruginosa

(2019) Samuel J. T. Wardell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections

(2019) Juan P. Horcajada et al.   CLINICAL MICROBIOLOGY REVIEWS

In Vitro Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Clinical Isolates of Meropenem-Non-Susceptible Pseudomonas aeruginosa: A Two-Center Study

(2019) Hasan Cenk Mirza et al.   Journal of Global Antimicrobial Resistance

Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model

(2018) Lindsay M. Avery et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Interplay between MexAB-OprM and MexEF-OprN in clinical isolates of Pseudomonas aeruginosa

(2018) Gertrudis Horna et al.   Scientific Reports

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

(2015) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

(2014) Dilip Nathwani et al.   Antimicrobial Resistance and Infection Control